{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:56:53Z","timestamp":1785902213098,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006650.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T00:00:00Z","timestamp":1404777600000}}],"reference-count":88,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006650.pub4","type":"journal-article","created":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T17:07:53Z","timestamp":1404839273000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer"],"prefix":"10.1002","author":[{"given":"Elie A","family":"Akl","sequence":"first","affiliation":[{"name":"American University of Beirut; Department of Internal Medicine; Riad El Solh St Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara A","family":"Kahale","sequence":"additional","affiliation":[{"name":"American University of Beirut; Faculty of Medicine; Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Barba","sequence":"additional","affiliation":[{"name":"Regina Elena National Cancer Institute; Division of Medical Oncology B - Scientific Direction; Via Elio Chianesi 53 Rome Italy 00144"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Neumann","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Pontificia Universidad Cat\u00f3lica de Chile; Department of Internal Medicine, Evidence Based Health Care Program; Lira 44, Santiago Santiago Regi\u00f3n metropolitana Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawman","family":"Labedi","sequence":"additional","affiliation":[{"name":"State University of New York at Buffalo; Department of Medicine; ECMC CC-142 462 Grider Street Buffalo NY USA 14215"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Terrenato","sequence":"additional","affiliation":[{"name":"Regina Elena National Cancer Institute; Biostatistics-Scientific Direction; Via Elio Chianesi 53 Rome Italy 00144"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sperati","sequence":"additional","affiliation":[{"name":"Regina Elena National Cancer Institute; Biostatistics-Scientific Direction; Via Elio Chianesi 53 Rome Italy 00144"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Muti","sequence":"additional","affiliation":[{"name":"National Cancer Institute Regina Elena; Department of Epidemiology; Via Elio Chianesi 53 Rome Italy 00144"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Sch\u00fcnemann","sequence":"additional","affiliation":[{"name":"McMaster University; Departments of Clinical Epidemiology and Biostatistics and of Medicine; 1280 Main Street West Hamilton ON Canada L8N 4K1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,7,8]]},"reference":[{"issue":"17","key":"10.1002\/14651858.CD006650.pub4-BIB0001|cit1","first-page":"2875","article-title":"Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients","volume":"108","author":"Cesarone","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clinical & Applied Thrombosis\/Hemostasis"},{"issue":"12","key":"10.1002\/14651858.CD006650.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006650.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD006650.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1200\/JCO.2005.03.133","article-title":"Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism","volume":"23","author":"Lee","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1067\/mva.2001.109336","article-title":"Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis","volume":"33","author":"Lopez-Beret","year":"2001","journal-title":"Journal of Vascular Surgery"},{"issue":"15","key":"10.1002\/14651858.CD006650.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejvs.2008.11.030","article-title":"A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis","volume":"37","author":"Romera","year":"2009","journal-title":"European Journal of Vascular and Endovascular Surgery"},{"issue":"18","key":"10.1002\/14651858.CD006650.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1160\/TH09-12-0870","article-title":"Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial","volume":"104","author":"Doormaal","year":"2010","journal-title":"Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1227\/00006123-199007000-00010","article-title":"The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors","volume":"27","author":"Altschuler","year":"1990","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub4-BIB0013|cit13","first-page":"235","article-title":"Management of thrombosis in the cancer patient","volume":"1","author":"Andrea","year":"2003","journal-title":"Journal of Supportive Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2796.1998.00317.x-i1","article-title":"Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation","volume":"244","author":"Astermark","year":"1998","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006650.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1055\/s-0037-1613395","article-title":"Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism","volume":"89","author":"Beckman","year":"2003","journal-title":"Thrombosis and Haemostasis"},{"issue":"10","key":"10.1002\/14651858.CD006650.pub4-BIB0016|cit16","first-page":"3207","article-title":"Thrombin generation and activity are increased in patients with cancer receiving sodium warfarin as secondary prophylaxis against venous thrombosis","volume":"90","author":"Bona","year":"1997","journal-title":"Blood"},{"issue":"5936","key":"10.1002\/14651858.CD006650.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/bmj.4.5936.96","article-title":"Blood and neoplastic diseases. Thrombosis: treatment and prophylaxis","volume":"4","author":"Browse","year":"1974","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub4-BIB0018|cit18","first-page":"3","article-title":"Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer","volume":"32","author":"Burgos","year":"1999","journal-title":"Lymphology"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0002-9378(16)32227-X","article-title":"Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy","volume":"147","author":"Clarke-Pearson","year":"1983","journal-title":"American Journal of Obstetrics & Gynecology"},{"issue":"11","key":"10.1002\/14651858.CD006650.pub4-BIB0020|cit20","first-page":"843","article-title":"Heparin prevents recurrent VTE in cancer patients","volume":"52","author":"Clenney","year":"2003","journal-title":"Journal of Family Practice"},{"issue":"5","key":"10.1002\/14651858.CD006650.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s002689900081","article-title":"Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial","volume":"20","author":"Das","year":"1996","journal-title":"World Journal of Surgery"},{"issue":"6","key":"10.1002\/14651858.CD006650.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejvs.2004.02.029","article-title":"Long-term treatment of deep venous thrombosis with a low molecular weight heparin (Tinzaparin): a prospective randomized trial","volume":"29","author":"Daskalopoulos","year":"2005","journal-title":"European Journal of Vascular and Endovascular Surgery"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub4-BIB0023|cit23","first-page":"522","article-title":"Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran","volume":"94","author":"Eriksson","year":"2005","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0024|cit24","unstructured":"Farred J Multifactorial etiology of cancer associated venous thrombosis: results from profiling of cancer patients recruited in a study of the secondary prevention of thrombosis with low molecular weight heparin 2004 ASCO Annual Meeting Proceedings 2004"},{"issue":"16","key":"10.1002\/14651858.CD006650.pub4-BIB0025|cit25","first-page":"765S","article-title":"Meta-analysis of the randomized comparisons between low-molecular weight heparin (LMWH) with oral anticoagulants (OA) for the long-term treatment of symptomatic venous thromboembolism (VTE): no difference in cancer-related mortality","volume":"23","author":"Ferretti","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD006650.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/annonc\/mdl092","article-title":"Does low-molecular-weight heparin influence cancer-related mortality?","volume":"17","author":"Ferretti","year":"2006","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD006650.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis - a randomized trial","volume":"293","author":"Fiessinger","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD006650.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0741-5214(99)70139-4","article-title":"Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis","volume":"30","author":"Gonzalez-Fajardo","year":"1999","journal-title":"Journal of Vascular Surgery"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0029|cit29","first-page":"S4","article-title":"Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis","volume":"2","author":"Hull","year":"1996","journal-title":"Clinical and Applied Thrombosis-Hemostasis"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD006650.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s003900070014","article-title":"A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis","volume":"37","author":"Hull","year":"2000","journal-title":"Intensivmedizin und Notfallmedizin"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.amjmed.2006.03.030","article-title":"Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms","volume":"120","author":"Hull","year":"2007","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.amjmed.2008.12.023","article-title":"Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome","volume":"122","author":"Hull","year":"2009","journal-title":"American Journal of Medicine"},{"issue":"2-3","key":"10.1002\/14651858.CD006650.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.disamonth.2005.03.011","article-title":"Long-term anticoagulation prophylaxis following acute thromboembolism","volume":"51","author":"Hyers","year":"2005","journal-title":"Disease-a-Month"},{"issue":"9","key":"10.1002\/14651858.CD006650.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1046\/j.1538-7836.2003.00364.x","article-title":"Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants","volume":"1","author":"Iorio","year":"2003","journal-title":"Journal of Thrombosis & Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1055\/s-0037-1613574","article-title":"Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis","volume":"89","author":"Kakkar","year":"2003","journal-title":"Thrombosis and Haemostasis - Stuttgart"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub4-BIB0036|cit36","first-page":"468","article-title":"Warfarin dose requirements in cancer and non-cancer","volume":"25","author":"King","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD006650.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1160\/TH05-01-0052","article-title":"Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients","volume":"93","author":"Kovacs","year":"2005","journal-title":"Thrombosis and Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1191\/1358863x05vm634oa","article-title":"Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism","volume":"10","author":"Kucher","year":"2005","journal-title":"Vascular Medicine"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1073274805012003S04","article-title":"Treatment of venous thromboembolism in cancer patients","volume":"12 Suppl 1","author":"Lee","year":"2005","journal-title":"Cancer Control"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2217\/14750708.3.4.461","article-title":"Dalteparin sodium in the management of thromboembolic disorder","volume":"3","author":"Lee","year":"2006","journal-title":"Therapy"},{"issue":"2","key":"10.1002\/14651858.CD006650.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1055\/s-0038-1649783","article-title":"Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis","volume":"74","author":"Levine","year":"1995","journal-title":"Thrombosis and Haemostasis"},{"issue":"7","key":"10.1002\/14651858.CD006650.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1046\/j.1538-7836.2003.00275.x","article-title":"From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer","volume":"1","author":"Levine","year":"2003","journal-title":"Journal of Thrombosis & Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-0037-1614412","article-title":"Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis","volume":"81","author":"Lopaciuk","year":"1999","journal-title":"Thrombosis and Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD006650.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1056\/NEJM199902043400503","article-title":"Lack of effect of coumarin in women with lymphedema after treatment for breast cancer","volume":"340","author":"Loprinzi","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"2-3","key":"10.1002\/14651858.CD006650.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0049-3848(03)00059-8","article-title":"An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial","volume":"109","author":"Massicotte","year":"2003","journal-title":"Thrombosis Research"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub4-BIB0046|cit46","first-page":"34","article-title":"New oral anticoagulant and cancer drug believed to be firsts","volume":"144","author":"McCan","year":"2000","journal-title":"Drug Topics"},{"issue":"12","key":"10.1002\/14651858.CD006650.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1001\/archinte.1987.00370120113020","article-title":"Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter?","volume":"147","author":"Olin","year":"1987","journal-title":"Archives of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006650.pub4-BIB0048|cit48","first-page":"805","article-title":"A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy","volume":"84","author":"Palareti","year":"2000","journal-title":"Thrombosis and Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub4-BIB0049|cit49","first-page":"322","article-title":"Therapy of deep vein thrombosis with low molecular weight heparin, compression and walking exercises","volume":"7","author":"Partsch","year":"2001","journal-title":"Anales de Cirugia Cardiaca y Cirugia Vascular"},{"issue":"8","key":"10.1002\/14651858.CD006650.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/MBC.0b013e3283401406","article-title":"Comparison of tinzaparin and acenocoumarol for the secondary prevention of venous thromboembolism: a multicentre, randomized study","volume":"21","author":"P\u00e9rez-de-Llano","year":"2010","journal-title":"Blood Coagulation Fibrinolysis"},{"issue":"20","key":"10.1002\/14651858.CD006650.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1161\/01.CIR.103.20.2453","article-title":"Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis","volume":"103","author":"Pinede","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD006650.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0038-1648837","article-title":"Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis","volume":"72","author":"Pini","year":"1994","journal-title":"Thrombosis and Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1538-7836.2006.01795.x","article-title":"Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months","volume":"4","author":"Schulman","year":"2006","journal-title":"Journal of Thrombosis & Haemostasis"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/ajhp\/62.22_Supplement_5.S7","article-title":"Considerations and challenges with existing treatments for thrombosis in cancer patients","volume":"62","author":"Schwartz","year":"2005","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/ebm.8.3.85","article-title":"In patients with cancer and venous thromboembolism (VTE), enoxaparin was as effective as warfarin for VTE prophylaxis and reduced fatal haemorrhage","volume":"8","author":"Scott","year":"2003","journal-title":"Evidence Based Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0025-7125(16)31117-8","article-title":"Diagnosis and treatment of recurrent venous thromboembolism","volume":"68","author":"Shattil","year":"1984","journal-title":"Medical Clinics of North America"},{"issue":"21","key":"10.1002\/14651858.CD006650.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/blood.V116.21.190.190","article-title":"The optimal duration of anticoagulant therapy in patients with cancer-related deep vein thrombosis: the advantage of using residual vein thrombosis (the Cancer-DACUS Study)","volume":"116","author":"Siragusa","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD006650.pub4-BIB0058|cit58","first-page":"1317","article-title":"Optimizing the duration of anticoagulation therapy for venous thrombosis","volume":"160","author":"Solymoss","year":"1999","journal-title":"Canadian Medical Association Journal"},{"issue":"11","key":"10.1002\/14651858.CD006650.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"102B","DOI":"10.1182\/blood.V104.11.4065.4065","article-title":"Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy","volume":"104","author":"Stine","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD006650.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"903","DOI":"10.6004\/jnccn.2006.0075","article-title":"Long-term therapy of venous thromboembolism in cancer patients","volume":"4","author":"Streiff","year":"2006","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub4-BIB0061|cit61","first-page":"134","article-title":"Treatment of deep vein thrombosis with low molecular weight heparins at home","volume":"20","author":"Suarez Alvarez","year":"2003","journal-title":"Anales de Medicina Interna"},{"issue":"8","key":"10.1002\/14651858.CD006650.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1046\/j.1538-7836.2003.00293.x","article-title":"Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation","volume":"1","author":"Taliani","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0063|cit63","first-page":"215","article-title":"Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis","volume":"28","author":"Tedoldi","year":"1993","journal-title":"Clinical Trials and Meta-Analysis"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub4-BIB0064|cit64","first-page":"559","article-title":"Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial","volume":"84","author":"Veiga","year":"2000","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub4-BIB0065|cit65","first-page":"296","article-title":"Treatment of deep vein thrombosis with oral anticoagulants ill patients with malignancy: prospective cohort study","volume":"43","author":"Vucic","year":"2002","journal-title":"Croatian Medical Journal"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0066|cit66","unstructured":"Longheva Ongoing study August 2010"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/1471-2407-13-284","article-title":"CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. PROTOCOL","volume":"13","author":"Lee","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"TPS9149","DOI":"10.1200\/jco.2012.30.15_suppl.tps9149","article-title":"CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting","volume":"Suppl","author":"Lee","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0069|cit69","unstructured":"ALICAT Ongoing study March 2013"},{"issue":"6","key":"10.1002\/14651858.CD006650.pub4-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006650.pub3","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer","author":"Akl","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006650.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"e57132","DOI":"10.1371\/journal.pone.0057132","article-title":"Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers","volume":"8","author":"Akl","year":"2013","journal-title":"PloS One"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006650.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000081508","article-title":"Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months","volume":"33","author":"Conti","year":"2003","journal-title":"Pathophysiology of Haemostasis & Thrombosis"},{"issue":"9","key":"10.1002\/14651858.CD006650.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jclinepi.2013.03.014","article-title":"Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers","volume":"66","author":"Ebrahim","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-0038-1657514","article-title":"Prevention of post-operative deep leg vein thrombosis in patients with cancer","volume":"78","author":"Gallus","year":"1997","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0076|cit76","first-page":"383","article-title":"Clinical expertise in the era of evidence-based medicine and patient choice","volume":"83 Suppl 1","author":"Haynes","year":"2002","journal-title":"Vox Sanguinis"},{"issue":"6","key":"10.1002\/14651858.CD006650.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0078|cit78","unstructured":"Higgins J Publication bias and funnel plots Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 2006 151 4"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0079|cit79","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1055\/s-0038-1646191","article-title":"Low molecular weight heparin","volume":"70","author":"Hirsh","year":"1993","journal-title":"Thrombosis and Haemostasis"},{"issue":"17","key":"10.1002\/14651858.CD006650.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"Hutten","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0002-9610(70)80023-X","article-title":"Deep vein thrombosis of the leg. Is there a \"high risk\" group?","volume":"120","author":"Kakkar","year":"1970","journal-title":"American Journal of Surgery"},{"issue":"5","key":"10.1002\/14651858.CD006650.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00005792-199909000-00001","article-title":"Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data","volume":"78","author":"Levitan","year":"1999","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0084|cit84","unstructured":"NCT00067093 Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT) clinicaltrials.gov\/ct\/show\/NCT00067093"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006650.pub4-BIB0086|cit86","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"issue":"25","key":"10.1002\/14651858.CD006650.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"Sorensen","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub4-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002001","article-title":"Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism","author":"Heijden","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006650.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006650.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:02:19Z","timestamp":1628546539000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006650.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,8]]},"references-count":88,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006650.pub4","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD006650.pub5","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,8]]}}}